Courtesy of Benzinga.
Mylan Inc. (NYSE: MYL) today announced that the company and its subsidiary, Mylan Pharmaceuticals Inc., have resolved the defamation and other related litigation filed by Mylan against the Pittsburgh Post-Gazette and two of its reporters. In connection with the resolution, the parties have agreed to the following statement:
“The litigation has been resolved to the satisfaction of both parties. The Post-Gazette did not find and did not intend to report that Mylan had manufactured or distributed any defective drugs. The Post-Gazette regrets if any reader of the article thought otherwise.”
For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.